Literature DB >> 22491271

Hemacord approval may foreshadow regulatory creep for HSC therapies.

Malorye Allison.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22491271     DOI： 10.1038/nbt0412-304

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

1.  Banking on cord blood stem cells.

Authors:  Sarah Webb
Journal:  Nat Biotechnol       Date:  2013-07       Impact factor: 54.908

Review 2.  Drug discovery and development for rare genetic disorders.

Authors:  Wei Sun; Wei Zheng; Anton Simeonov
Journal:  Am J Med Genet A       Date:  2017-07-21       Impact factor: 2.802

Review 3.  Biological Products: Cellular Therapy and FDA Approved Products.

Authors:  Ali Golchin; Tahereh Zarnoosheh Farahany
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

4.  Fresh from the biotech pipeline--2012.

Authors:  Randy Osborne
Journal:  Nat Biotechnol       Date:  2013-02       Impact factor: 54.908

5.  Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells.

Authors:  Peter W Andrews; Joy Cavagnaro; Joy Cavanagro; Robert Deans; Ellen Feigal; Ellen Feigel; Ed Horowitz; Armand Keating; Mahendra Rao; Marc Turner; Ian Wilmut; Shinya Yamanaka
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

6.  Biomimetic Surface Patterning Promotes Mesenchymal Stem Cell Differentiation.

Authors:  Anita Shukla; John H Slater; James C Culver; Mary E Dickinson; Jennifer L West
Journal:  ACS Appl Mater Interfaces       Date:  2015-12-17       Impact factor: 9.229

Review 7.  Nanoparticles based stem cell tracking in regenerative medicine.

Authors:  Matthew Edmundson; Nguyen Tk Thanh; Bing Song
Journal:  Theranostics       Date:  2013-07-23       Impact factor: 11.556
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.